Special Issue "Establishment and Characterization of Novel Patient-Derived Cancer Cell Line"
Deadline for manuscript submissions: 31 March 2022.
Interests: paient-derived cancer model; rare cancer research; sarcoma; expanded indication; biobank; viral carcinogenesis; transcriptomics; exosome/miRNA; tissue culture; primary culture
Interests: rare cancer research; sarcoma; biobank; precision medicine; biomarker development; target discovery; patient-derived cancer model; proteogenomics; proteomics; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue in Cancers: Ewing Sarcoma
Special Issue in Cells: Current Applications of Patient-Derived Cancer Model
Patient-derived cancer cell lines have facilitated fundamental progress in cancer biology and revolutionized medicine. They enable functional studies of novel genes and proteins, allow the evaluation of anti-tumor effects of novel anti-cancer agents in a high-throughput manner, and provide insights into molecular mechanisms underlying the malignant behavior of cancer cells. The advent of genomics has identified a large number of intriguing genes, and such cell lines are required to interpret their functional properties and the significance of their aberrant regulation in the clinical tumors. The utility of cell lines has been widely recognized, and they have been deposited in cell banks to be shared with the research community. Although cell lines are important tools in cancer research, several critical issues remain to be addressed to improve their utility and possible applications. For example, according to cell line databases, such as Cellosaurus, only a limited number of cell lines have been established for any given cancer; moreover, for a considerable number of cancers, especially rare cancers, no cell lines have been established. Considering the heterogeneity of tumor tissues and the tissue-independence of gene function, we need to expand the collection of cell lines and share them with the research community.
The Special Issue will highlight the establishment and characterization of novel cell lines using clinical materials. Original contributions related to novel cell lines, characterization of novel and existing cell lines, technical notes for cell line establishment and application, and review articles of relevant topics are invited for publication in this Special Issue.
Dr. Yuki Yoshimatsu
Dr. Tadashi Kondo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Patient-derived cancer model
- Cell line
- Primary culture
- Precision medicine
- Therapeutic target